Docetaxel Injection
Product Images NDC 43066-044

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Docetaxel (NDC 43066-044). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Baxter Healthcare Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Docetaxel-figure-1 (Docetaxel Figure 1)

This text appears to show a chart or graph depicting disease-free survival time in months, with the y-axis labeled as "OFS Probability (%)" and the x-axis as "Months." The graph is labeled as "Figure 1-TAX316" and seems to show data points representing percentages over time.*

FDA Label Image

Docetaxel-figure-10 (Docetaxel Figure 10)

Not available.*

FDA Label Image

Docetaxel-figure-2 (Docetaxel Figure 2)

This is a description of Figure 2 showing the TAX316 Overall Survival Kaplan-Meier Curve. The graph displays survival probability over time in months.*

FDA Label Image

Docetaxel-figure-3 (Docetaxel Figure 3)

This is a survival analysis graph comparing the survival curves of patients treated with Docetaxel 75 mg/m² versus Best Supportive Care (BSC). The graph shows the cumulative probability of survival over time, with the x-axis representing survival time in months and the y-axis displaying the cumulative probability. The log-rank test resulted in a p-value of 0.010, indicating a statistically significant difference between the two treatment groups in terms of overall survival.*

FDA Label Image

Docetaxel-figure-4 (Docetaxel Figure 4)

FDA Label Image

Docetaxel-figure-5 (Docetaxel Figure 5)

This text shows a figure of survival probability with TAX327 Survival K-M Curves. It displays the survival time in months on the x-axis and the survival probability on the y-axis. The curve illustrates the probability of survival over different time intervals, providing valuable information for analyzing survival rates.*

FDA Label Image

Docetaxel-figure-6 (Docetaxel Figure 6)

FDA Label Image

Docetaxel-figure-7 (Docetaxel Figure 7)

This text shows a K-M curve illustrating the survival data for the Gastric Cancer Study (TAX325). The curve represents survival time in months and provides insights into the survival rates of the study participants over the specified period.*

FDA Label Image

Docetaxel-figure-8 (Docetaxel Figure 8)

FDA Label Image

Docetaxel-figure-9 (Docetaxel Figure 9)

FDA Label Image

Docetaxel-structure (Docetaxel Structure)

FDA Label Image

Image-01 (Image 01)

This text provides information about a medication manufactured by Baxter Healthcare Corporation. The product is a 20 mg/2 mL solution for intravenous use, with each mL containing 10 mg of the active ingredient. It comes in a single-dose vial that should be discarded after use. The medication is ready to be added to an infusion solution, but the concentration should be checked before preparation. The package insert should be referred to for complete instructions. It is also noted that the medication is a cytotoxic agent and should be handled with caution. Storage instructions indicate to store the product at a temperature between 20°C to 25°C.*

FDA Label Image

Image-02 (Image 02)

FDA Label Image

Image-03 (Image 03)

This text provides details about Docetaxel Injection, a cytotoxic agent for intravenous use. It comes in a 80 mg/8 mL multiple-dose vial. The composition includes 10 mg of Docetaxel USP per mL along with other components. It is advised to check concentration before preparation. The product should be stored at 20° to 25°C and protected from light. Additional information on dosage can be found in the insert. The manufacturer is Baxter Healthcare Corporation based in Deerfield, IL, USA.*

FDA Label Image

Image-04 (Image 04)

Not available*

FDA Label Image

Image-05 (Image 05)

This text is a detailed description of a medication labeled as NDC 43066-048-01, with dosage information of 160 mg/16 mL (10 mg/mL) for intravenous use. The medication is a cytotoxic agent containing Docetaxel, Polysorbate, Citric Acid, Dehydrated Alcohol, and Polyethylene Glycol. It is a multiple-dose vial that should be stored at 20° to 25°C protected from light. Instructions for preparation and administration can be found in the package insert. The usual dosage should be followed as per the insert. This medication is manufactured for Baxter Healthcare Corporation in Deerfield, IL, USA.*

FDA Label Image

Image-06 (Image 06)

This is a product label for a Docetaxel Injection, USP, manufactured by Baxter Healthcare Corporation. The medication is a cytotoxic agent and is presented in a multiple-dose vial. Each mL contains 10mg of Docetaxel, USP, along with other components. The usual dosage and storage instructions are provided on the label. It is intended for intravenous use only and must be added to an infusion solution. The manufacturer details and dosage information can be found in the package insert. It is important to check the concentration before preparation and to keep the medication out of reach of children.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.